MCMedicalCodingSoftware
C9149

C9149: Injection, teplizumab-mzwv, 5 mcg

HCPCSTerminatedBETOS O1E

C9149 is a HCPCS Level II code for injection, teplizumab-mzwv, 5 mcg. It belongs to the Outpatient Prospective Payment System section. It was terminated on June 30, 2023 and is not valid on new claims.

This code has been terminated

CMS terminated C9149 on June 30, 2023. It stays in the file as history: a claim you are auditing from before that date may legitimately carry it, but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.

Medicare coverage: Special coverage instructions apply

There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.

From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q4-Oct. This states Medicare’s position on the code, not on your particular claim.

The CMS record for C9149

Long descriptor
Injection, teplizumab-mzwv, 5 mcg

The official wording. This is what the code means.

Short descriptor
Inj, teplizumab-mzwv, 5 mcg

CMS's 28-character form, which is what shows up on a remittance advice.

Added
April 1, 2023

When CMS introduced the code.

Terminated
June 30, 2023

When CMS retired it.

BETOS
O1E

Berenson-Eggers Type of Service: CMS's own analytic grouping.

Pricing indicator
53: Other

Statute.

Codes adjacent to C9149

HCPCS has no hierarchy: related items simply sit next to each other in the numbering. If C9149 is not quite right, the correct code is very often within a few positions of it.

  • C9141Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl (jivi), 1 i.u.terminated
  • C9142Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mgterminated
  • C9143Cocaine hydrochloride nasal solution (numbrino), 1 mg
  • C9144Injection, bupivacaine (posimir), 1 mg
  • C9145Injection, aprepitant, (aponvie), 1 mgterminated
  • C9146Injection, mirvetuximab soravtansine-gynx, 1 mgterminated
  • C9147Injection, tremelimumab-actl, 1 mgterminated
  • C9148Injection, teclistamab-cqyv, 0.5 mgterminated
  • C9150Xenon xe-129 hyperpolarized gas, diagnostic, per study doseterminated
  • C9151Injection, pegcetacoplan, 1 mgterminated
  • C9152Injection, aripiprazole, (abilify asimtufii), 1 mgterminated
  • C9153Injection, amisulpride, 1 mgterminated
  • C9154Injection, buprenorphine extended-release (brixadi), 1 mgterminated
  • C9155Injection, epcoritamab-bysp, 0.16 mgterminated
  • C9156Flotufolastat f 18, diagnostic, 1 millicurieterminated
  • C9157Injection, tofersen, 1 mgterminated
HCPCS Level II2026Q4-Oct· effective October 1, 2026